SuperworthTectonic Therapeutic EPS TECX
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- −$4.57
- Latest quarter, Q2 FY26
- −$1.18
- Fiscal year 2025
- −$4.05
Tectonic Therapeutic's earnings per share was −$4.57 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.18.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$4.05 | n/a |
| FY2024 | −$17.35 | n/a |
| FY2023 | −$25.37 | n/a |
| FY2022 | −$28.92 | n/a |
| FY2021 | −$33.48 | n/a |
| FY2020 | −$39.72 | n/a |
| FY2019 | −$32.16 | n/a |
| FY2018 | −$103.80 | n/a |
| FY2017 | −$99.60 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.18 | n/a | −$4.57 | |
| Q1 FY26 | −$1.34 | n/a | −$4.46 | |
| Q4 FY25 | −$1.03 | n/a | −$4.05 | |
| Q3 FY25 | −$1.02 | n/a | −$3.86 | |
| Q2 FY25 | −$1.07 | n/a | −$4.04 | |
| Q1 FY25 | −$0.93 | n/a | −$7.31 | |
| Q4 FY24 | −$0.84 | n/a | −$17.35 | |
| Q3 FY24 | −$1.20 | n/a | −$18.91 | |
| Q2 FY24 | −$4.34 | n/a | −$25.33 | |
| Q1 FY24 | −$10.97 | n/a | −$29.50 | |
| Q4 FY23 | −$2.40 | n/a | −$25.37 | |
| Q3 FY23 | −$7.62 | n/a | −$29.81 |
Against its peers
Companies in Biotechnology nearest Tectonic Therapeutic's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| TECXTectonic Therapeutic | −$4.57 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Tectonic Therapeutic
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.